Inhibitory effects of baicalein against herpes simplex virus type 1.
10.1016/j.apsb.2020.06.008
- Author:
Zhuo LUO
1
;
Xiu-Ping KUANG
1
;
Qing-Qing ZHOU
1
;
Chang-Yu YAN
1
;
Wen LI
1
;
Hai-Biao GONG
1
;
Hiroshi KURIHARA
1
;
Wei-Xi LI
2
;
Yi-Fang LI
1
;
Rong-Rong HE
1
Author Information
1. Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, College of Pharmacy, College of Pharmacy, Jinan University, Guangzhou 612505, China.
2. Yunnan University of Traditional Chinese Medicine, Kunming 650550, China.
- Publication Type:Journal Article
- Keywords:
Anti-HSV-1;
Baicalein;
CC50, 50% cytotoxic concentration;
DCFH-DA, 2′,7′-dichlorofluorescin diacetate;
EC50, 50% effective concentration;
GB, glycoprotein B;
HSV-1 infection;
HSV-1, herpes simplex virus types 1;
ICP, infected cell polypeptide;
IKK-β phosphorylation;
IKK-β, IκB kinase beta;
IL-1β, interleukin 1 beta;
IL-6, interleukin 6;
IκB-α, inhibitor of NF-κB alpha;
LPS, lipopolysaccharides;
MOI, multiplicity of infection;
NAC, N-acetyl-l-cysteine;
NF-κB activation;
NF-κB, nuclear factor kappa-B;
PFU, plaque-forming units;
PGA1, prostaglandin A1;
ROS, reactive oxygen species;
SI, selectivity index;
TG, trigeminal ganglia;
TNF-α, tumor necrosis factor alpha;
Viral inactivation;
dpi, days post-infection;
p-IKK-β, phosphorylated-IKK beta;
p-IκB-α, phosphorylated-IκB alpha
- From:
Acta Pharmaceutica Sinica B
2020;10(12):2323-2338
- CountryChina
- Language:English
-
Abstract:
Herpes simplex virus type 1 (HSV-1) is a ubiquitous and widespread human pathogen, which gives rise to a range of diseases, including cold sores, corneal blindness, and encephalitis. Currently, the use of nucleoside analogs, such as acyclovir and penciclovir, in treating HSV-1 infection often presents limitation due to their side effects and low efficacy for drug-resistance strains. Therefore, new anti-herpetic drugs and strategies should be urgently developed. Here, we reported that baicalein, a naturally derived compound widely used in Asian countries, strongly inhibited HSV-1 replication in several models. Baicalein was effective against the replication of both HSV-1/F and HSV-1/Blue (an acyclovir-resistant strain)
